Fresenius Kabi USA has issued voluntary nationwide recall of four lots of benztropine mesylate injection, USP 2mg/2mL (1mg/mL), in 2mL single dose vials.
Being conducted at the user level, the recall is due to the potential presence of glass particles (glass delamination) in the vials.
The product that may appear with APP or Nexus Pharmaceuticals lables is manufactured by Allergy Laboratories and distributed by Fresenius Kabi.
Used as an adjunct in the therapy of all forms of parkinsonism, Benztropine Mesylate is also indicated for the control of extrapyramidal disorders due to neuroleptic drugs, except tardive dyskinesia.
Source:
http://drugdelivery.pharmaceutical-business-review.com/news/fresenius-kabi-recalls-benztropine-mesylate-injection-010713
